{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-001069","form_type":"8-K","ticker":"LIXT","cik":"0001335105","company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","filed_at":"2025-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.377859+00:00","generated_at":"2026-05-28T09:57:59.175287+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lixte Biotechnology enters $1.7M at-the-market sales agreement with WallachBeth Capital","bullets":["Entered ATM sales agreement to sell up to $1.7M of common stock.","Agent commission 3.5% of gross sales; up to $50K expense reimbursement.","Net proceeds for working capital and development of lead compound LB-100.","Sales at market prices on Nasdaq or other methods per Rule 415.","Company not obligated to sell any shares under the agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-001069","json":"https://secwatch.observer/filing/0001493152-25-001069.json","markdown":"https://secwatch.observer/filing/0001493152-25-001069.md","text":"https://secwatch.observer/filing/0001493152-25-001069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1335105/000149315225001069/0001493152-25-001069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1335105/000149315225001069/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T09:57:59.175287+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}